Patents Assigned to Pacific Northwest Research Institute
-
Patent number: 11446271Abstract: Embodiments provided herein include methods, compositions, and uses of aromatic alcohols to increase the potency of antifungal agents.Type: GrantFiled: July 13, 2020Date of Patent: September 20, 2022Assignee: PACIFIC NORTHWEST RESEARCH INSTITUTEInventors: Catherine Ludlow, Aimee Dudley, Zhihao Tan
-
Patent number: 10751317Abstract: Embodiments provided herein include methods, compositions, and uses of aromatic alcohols to increase the potency of antifungal agents.Type: GrantFiled: October 6, 2015Date of Patent: August 25, 2020Assignee: PACIFIC NORTHWEST RESEARCH INSTITUTEInventors: Catherine Ludlow, Aimee M. Dudley, Zhihao Tan
-
Publication number: 20160033512Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.Type: ApplicationFiled: July 27, 2015Publication date: February 4, 2016Applicant: PACIFIC NORTHWEST RESEARCH INSTITUTEInventors: Ingegerd Hellstrom, Jeffrey A. Ledbetter, Martha Hayden-Ledbetter
-
Patent number: 9090712Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.Type: GrantFiled: August 6, 2009Date of Patent: July 28, 2015Assignee: PACIFIC NORTHWEST RESEARCH INSTITUTEInventors: Ingegerd Hellstrom, Jeffrey A. Ledbetter, Martha Hayden-Ledbetter
-
Patent number: 8268561Abstract: A method of genetically screening large numbers of individuals to identify those individuals requiring follow-up testing for active Type I diabetes (T1D) is provided. The method includes obtaining a nucleic-acid containing biological sample from each individual and testing for the presence of specific combinations of HLA II alleles in the sample.Type: GrantFiled: April 8, 2009Date of Patent: September 18, 2012Assignee: Pacific Northwest Research InstituteInventors: William Hagopian, Hui Peng
-
Publication number: 20110104675Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble forms of mesothelin polypeptides, including mesothelin related antigen (MRA). In particular the invention provides a nucleic acid sequence encoding MRA and an MRA variant. The invention also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a mesothelin polypeptide with a molecule naturally occurring in soluble form in a sample from such a subject, and by hybridization screening using an MRA nucleotide sequence, as well as other related advantages.Type: ApplicationFiled: May 17, 2010Publication date: May 5, 2011Applicant: Pacific Northwest Research InstituteInventors: Nathalie Scholler, Ingegerd Hellstrom, Karl Erik Hellstrom
-
Publication number: 20100047818Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.Type: ApplicationFiled: August 6, 2009Publication date: February 25, 2010Applicant: PACIFIC NORTHWEST RESEARCH INSTITUTEInventors: Ingegerd Hellstrom, Jeffrey A. Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20090311697Abstract: A method of genetically screening large numbers of individuals to identify those individuals requiring follow-up testing for active Type I diabetes (T1D) is provided. The method includes obtaining a nucleic-acid containing biological sample from each individual and testing for the presence of specific combinations of HLA II alleles in the sample.Type: ApplicationFiled: April 8, 2009Publication date: December 17, 2009Applicant: PACIFIC NORTHWEST RESEARCH INSTITUTEInventors: William HAGOPIAN, Hui PENG
-
Publication number: 20090104684Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.Type: ApplicationFiled: August 8, 2007Publication date: April 23, 2009Applicants: Pacific Northwest Research Institute, University of WashingtonInventors: Michel Schummer, INGEGERD HELLSTROM, Karl Erik Hellstrom, JEFFREY A. LEDBETTER, MARTHA HAYDEN-LEDBETTER
-
Patent number: 7270960Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.Type: GrantFiled: August 28, 2002Date of Patent: September 18, 2007Assignee: Pacific Northwest Research InstituteInventors: Ingegerd Hellstrom, Jeffrey A. Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20040219161Abstract: The invention provides compositions and methods directed to cell surface receptor antigen specific vaccines. More specifically, vaccines are provided that induce or enhance host antibody titers specific for cell surface receptor antigens and that include recombinant expression constructs containing nucleic acids encoding a target cell surface receptor antigen and one or more immune response altering molecules, or the expressed products themselves.Type: ApplicationFiled: January 20, 2004Publication date: November 4, 2004Applicant: Pacific Northwest Research InstituteInventors: Nathalie B. Scholler, Mary L. Disis, Ingegerd Hellstrom, Karl Erik Hellstrom
-
Patent number: 6770445Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble forms of mesothelin polypeptides, including mesothelin related antigen (MRA). In particular the invention provides a nucleic acid sequence encoding MRA and an MRA variant. The invention also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a mesothelin polypeptide with a molecule naturally occurring in soluble form in a sample from such a subject, and by hybridization screening using an MRA nucleotide sequence, as well as other related advantages.Type: GrantFiled: February 25, 2000Date of Patent: August 3, 2004Assignee: Pacific Northwest Research InstituteInventors: Nathalie B. Scholler, Ingegerd Hellstrom, Karl Erik Hellstrom
-
Publication number: 20040142396Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble forms of mesothelin polypeptides, including mesothelin related antigen (MRA). In particular the invention provides a nucleic acid sequence encoding MRA and an MRA variant. The invention also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a mesothelin polypeptide with a molecule naturally occurring in soluble form in a sample from such a subject, and by hybridization screening using an MRA nucleotide sequence, as well as other related advantages.Type: ApplicationFiled: February 13, 2004Publication date: July 22, 2004Applicant: Pacific Northwest Research InstituteInventors: Nathalie B. Scholler, Ingegerd Hellstrom, Karl Erik Hellstrom
-
Patent number: 6734172Abstract: The invention provides compositions and methods directed to cell surface receptor antigen specific vaccines. More specifically, vaccines are provided that induce or enhance host antibody titers specific for cell surface receptor antigens and that include recombinant expression constructs containing nucleic acids encoding a target cell surface receptor antigen and one or more immune response altering molecules, or the expressed products themselves.Type: GrantFiled: November 16, 1999Date of Patent: May 11, 2004Assignee: Pacific Northwest Research InstituteInventors: Nathalie B. Scholler, Mary L. Disis, Ingegerd Hellstrom, Karl Erik Hellstrom
-
Publication number: 20030108965Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.Type: ApplicationFiled: August 28, 2002Publication date: June 12, 2003Applicant: Pacific Northwest Research InstituteInventors: Michel Schummer, Ingegerd Hellstrom, Karl Erik Hellstrom, Jeffrey A. Ledbetter, Martha Hayden-Ledbetter
-
Patent number: 6214550Abstract: Methods of screening for a tumor or tumor progression to the metastatic state are disclosed. The screening methods are based on the characterization of DNA by principal components analysis of spectral data yielded by Fourier transform-infrared spectroscopy of DNA samples. The methods are applicable to a wide variety of DNA samples and cancer types. A model developed using multivariate normal distribution equations and discriminant analysis is particularly well suited for distinguishing primary cancerous tissue from metastatic cancerous tissue.Type: GrantFiled: June 25, 1998Date of Patent: April 10, 2001Assignee: Pacific Northwest Research InstituteInventor: Donald C. Malins